vorinostat has been researched along with Bone Cancer in 11 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteosarcoma is the most common primary bone cancer in children and is a highly malignant disease, in which 25% of patients present with metastasis at diagnosis." | 5.43 | Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. ( Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C, 2016) |
| "Vorinostat-treated and control mice without tumors were also examined." | 5.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| "Osteosarcoma is the most common primary bone cancer in children and is a highly malignant disease, in which 25% of patients present with metastasis at diagnosis." | 1.43 | Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines. ( Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C, 2016) |
| "A local cytotoxic therapy in the treatment of osteosarcoma and chondrosarcoma might improve the rate of metastasis and survival of patients." | 1.40 | HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma. ( Becker, M; Eckhard, L; Graf, C; Proschek, D; Rommens, PM; Theobald, M; Tonak, M; Wehler, TC, 2014) |
| "Several cancers, however, fail to respond to TRAIL's antineoplastic effects." | 1.38 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012) |
| "Vorinostat-treated and control mice without tumors were also examined." | 1.36 | The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. ( Akech, J; Bedard, K; Dhillon, RJ; Hussain, S; Li, X; Lian, JB; McGee-Lawrence, ME; Pratap, J; Stein, GS; Stein, JL; Szabo, G; van Wijnen, AJ; Westendorf, JJ; Wixted, JJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (90.91) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| He, XT | 1 |
| Hu, XF | 1 |
| Zhu, C | 1 |
| Zhou, KX | 1 |
| Zhao, WJ | 1 |
| Zhang, C | 1 |
| Han, X | 1 |
| Wu, CL | 1 |
| Wei, YY | 1 |
| Wang, W | 1 |
| Deng, JP | 1 |
| Chen, FM | 1 |
| Gu, ZX | 1 |
| Dong, YL | 1 |
| Shats, I | 1 |
| Gatza, ML | 1 |
| Liu, B | 1 |
| Angus, SP | 1 |
| You, L | 1 |
| Nevins, JR | 1 |
| Tonak, M | 1 |
| Becker, M | 1 |
| Graf, C | 1 |
| Eckhard, L | 1 |
| Theobald, M | 1 |
| Rommens, PM | 1 |
| Wehler, TC | 1 |
| Proschek, D | 1 |
| Mu, X | 1 |
| Brynien, D | 1 |
| Weiss, KR | 1 |
| Unland, R | 1 |
| Clemens, D | 2 |
| Heinicke, U | 1 |
| Potratz, JC | 1 |
| Hotfilder, M | 2 |
| Fulda, S | 1 |
| Wardelmann, E | 1 |
| Frühwald, MC | 1 |
| Dirksen, U | 2 |
| Blattmann, C | 1 |
| Oertel, S | 1 |
| Thiemann, M | 1 |
| Dittmar, A | 1 |
| Roth, E | 1 |
| Kulozik, AE | 1 |
| Ehemann, V | 1 |
| Weichert, W | 1 |
| Huber, PE | 1 |
| Stenzinger, A | 1 |
| Debus, J | 1 |
| Pattenden, SG | 1 |
| Simon, JM | 1 |
| Wali, A | 1 |
| Jayakody, CN | 1 |
| Troutman, J | 1 |
| McFadden, AW | 1 |
| Wooten, J | 1 |
| Wood, CC | 1 |
| Frye, SV | 1 |
| Janzen, WP | 1 |
| Davis, IJ | 1 |
| Pettke, A | 1 |
| Klco-Brosius, S | 1 |
| Schaefer, C | 1 |
| Potratz, J | 1 |
| Murahari, S | 1 |
| Jalkanen, AL | 1 |
| Kulp, SK | 1 |
| Chen, CS | 1 |
| Modiano, JF | 1 |
| London, CA | 1 |
| Kisseberth, WC | 1 |
| Pratap, J | 1 |
| Akech, J | 1 |
| Wixted, JJ | 1 |
| Szabo, G | 1 |
| Hussain, S | 1 |
| McGee-Lawrence, ME | 1 |
| Li, X | 1 |
| Bedard, K | 1 |
| Dhillon, RJ | 1 |
| van Wijnen, AJ | 1 |
| Stein, JL | 1 |
| Stein, GS | 1 |
| Westendorf, JJ | 1 |
| Lian, JB | 1 |
| Sonnemann, J | 1 |
| Trommer, N | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Grauel, D | 1 |
| Palani, CD | 1 |
| Beck, JF | 1 |
11 other studies available for vorinostat and Bone Cancer
| Article | Year |
|---|---|
Suppression of histone deacetylases by SAHA relieves bone cancer pain in rats via inhibiting activation of glial cells in spinal dorsal horn and dorsal root ganglia.
Topics: Analgesics; Animals; Bone Neoplasms; Cancer Pain; Female; Ganglia, Spinal; Histone Deacetylase Inhib | 2020 |
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Proliferatio | 2013 |
HDAC inhibitor-loaded bone cement for advanced local treatment of osteosarcoma and chondrosarcoma.
Topics: Apoptosis; Biomechanical Phenomena; Bone Cements; Bone Neoplasms; Cell Proliferation; Cells, Culture | 2014 |
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Prol | 2015 |
Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; Etoposide; His | 2015 |
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibit | 2015 |
High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chromatin; Drug Design; Drug Evaluation, Pr | 2016 |
Suberanilohydroxamic acid (vorinostat) synergistically enhances the cytotoxicity of doxorubicin and cisplatin in osteosarcoma cell lines.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Neoplasms; Cell Growth | 2016 |
Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Topics: Animals; Bone Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dogs; Doxoru | 2017 |
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Topics: Animals; Bone and Bones; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Extr | 2010 |
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib | 2012 |